TN 100 Covey Drive Suite 307 Franklin, TN 37067





MEDICATION ORDERS Jubbonti (denosumab-bbdz)

doubling (de	enosumab-bbdz)	Date:			
		PATIENT IN	FORMATION			
Name:			DOB:			
Allergies:			Date of Referral:			
		REFERRA	L STATUS			
	☐ New Referral	☐ Dose or Freq	uency Change	☐ Order Renew	 ⁄al	
Warnings and Precaution						
https://www.accessdata.fda.g	ov/drugsattda_docs/l	abel/2024/761362s0	000lbl.pdf			
DIAGNOSIS AND ICD 10	CODE INDICATION	S				
100.10		NK ligand (RANKL) in	hibitor indicated	for treatment:		
ICD 10:		 □ of postmenopausal women with osteoporosis at high risk for fracture. □ to increase bone mass in men with osteoporosis at high risk for fracture □ of glucocorticoid-induced osteoporosis in men and women at high risk for fracture □ to increase bone mass in men at high risk for fracture receiving androgen deprivation 				
ICD 10:						
ICD 10:						
therapy for non metastatic prostate cancer						
□ to increase bone mass in women at high risk for fracture receiving adju aromatase inhibitor therapy for breast cancer					receiving adjuvant	
			1 /			
		REQUIRED DOG	CUMENTATION			
☐ Signed/Dated RX			☐ Pt Demographics			
☐ Recent Progress notes		☐ Pt Insurance information and picture of cards				
☐ Recent DEXA		☐ Recent CMP				
List Tried & Failed Therapie	s, including duration	of treatment (please	comment specifically	on bisphosphonat	es):	
1)						
2)						
		JUBBONTI /	MEDICATION ORDERS	5		
Dosing	□ 60mg SubQ every 6 months					
Refills:	☐ X 6 months	□ X 1 year	□ doses			
		DDECCIDED IN	EODAAATION!			
Prescriber Name:		PRESCIBER IN	IORMATION			
Office Phone:		Office Fax:		Office Email:		
Prescriber Signature:				Date:		
O						
ORDERING PROV	/IDED					
	IDEK					
Signature X			Date		_ Fax	

Provider _____ Phone ____ Provider NPI_____